Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women

Measuring inconsistency in meta-analyses

2003 • 53,662 citations

Cochrane Database of Systematic Reviews

2003 • 7,339 citations

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

2005 • 7,244 citations

Cancer incidence, mortality and prevalence worldwide

2004 • 3,893 citations

ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.

1896 • 1,633 citations

Globocan 2000 : cancer incidence, mortality and prevalence worldwide

2001 • 1,504 citations

ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.1

1896 • 1,240 citations

Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group

2001 • 1,019 citations

Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial

2000 • 990 citations

Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study

2000 • 841 citations

Survival Analysis: A Practical Approach.

1996 • 756 citations

Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial

2005 • 741 citations

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

2001 • 700 citations

Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine Treatment

2002 • 670 citations

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.

1998 • 647 citations

Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American Trial

2002 • 645 citations

Assessment of response to therapy in advanced breast cancer.A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland

1977 • 633 citations

Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over Study

2002 • 572 citations

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

2001 • 567 citations

WOODPECKERS' TONGUES

1976 • 553 citations

Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial

2000 • 531 citations

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

2008 • 480 citations

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.

1998 • 421 citations

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

1996 • 412 citations

Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol Acetate

2001 • 360 citations

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1996 • 341 citations

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor‐positive breast cancer

2006 • 330 citations

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women

2003 • 314 citations

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

1995 • 312 citations

Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis

2006 • 278 citations

Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer

1998 • 267 citations

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *

1996 • 261 citations

In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.

1995 • 241 citations

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women

2009 • 230 citations

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer

2003 • 228 citations

An open randomised trial of second-line endocrine therapy in advanced breast cancer

2003 • 190 citations

Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results

2003 • 174 citations

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma

1998 • 170 citations

The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study.

2000 • 148 citations

Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.

1989 • 136 citations

Anastrozole Versus Tamoxifen as First-Line Therapy in Postmenopausal Patients With Hormone-Dependent Advanced Breast Cancer

2003 • 134 citations

Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen

2003 • 127 citations

Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials

1996 • 121 citations

Randomized Phase III Trial Comparing the New Potent and Selective Third-Generation Aromatase Inhibitor Vorozole With Megestrol Acetate in Postmenopausal Advanced Breast Cancer Patients

1999 • 113 citations

Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.

1994 • 103 citations

First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer

1996 • 96 citations

Efficacy of tamoxifen following anastrozole (‘Arimidex’) compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women

2003 • 90 citations

POTENCY AND SELECTIVITY OF THE NON‐STEROIDAL AROMATASE INHIBITOR CGS 16949A IN POSTMENOPAUSAL BREAST CANCER PATIENTS

1990 • 86 citations

The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, ‘Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients’

2004 • 86 citations

Hormonal treatment for metastatic breast cancer. An eastern cooperative oncology group phase III trial comparing aminoglutethimide to tamoxifen

1994 • 72 citations

Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

2003 • 69 citations

A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer

1996 • 68 citations

Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Angeles, U.S.A.1

1999 • 68 citations

A randomized Phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma

1997 • 65 citations

Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90)

1997 • 65 citations

A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer.

1992 • 62 citations

Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.

1994 • 61 citations

Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer.

1986 • 58 citations

Recent advances in endocrine therapy of breast cancer

1997 • 53 citations

Aromatase inhibitors

1996 • 53 citations

Megestrol acetate versus aminoglutethimide for metastatic breast cancer

1989 • 52 citations

Letrozole in advanced breast cancer: the PO25 trial

2007 • 49 citations

Superiority of Letrozole to Tamoxifen in the First-Line Treatment of Advanced Breast Cancer: Evidence from Metastatic Subgroups and a Test of Functional Ability

2004 • 47 citations

Defining Clinical Benefit in Postmenopausal Patients With Breast Cancer Under Second-Line Endocrine Treatment: Does Quality of Life Matter?

1999 • 45 citations

The minimal effective exemestane dose for endocrine activity in advanced breast cancer

1997 • 44 citations

Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer

1994 • 44 citations

Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer

1999 • 42 citations

Efficacy of First-Line Letrozole Versus Tamoxifen as a Function of Age in Postmenopausal Women with Advanced Breast Cancer

2004 • 40 citations

Randomized Trial of Tamoxifen versus Aminoglutethimide and versus Combined Tamoxifen and Aminoglutethimide in Advanced Postmenopausal Breast Cancer

1988 • 40 citations

TREATMENT OF DISSEMINATED BREAST CANCER WITH TAMOXIFEN, AMINOGLUTETHIMIDE, HYDROCORTISONE, AND DANAZOL, USED IN COMBINATION OR SEQUENTIALLY

1984 • 39 citations

Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer

2002 • 39 citations

Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women

2000 • 36 citations

The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels

1997 • 35 citations

Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen

1992 • 34 citations

Randomized Trial Comparing Aminoglutethimide With High-Dose Medroxyprogesterone Acetate in Therapy for Advanced Breast Carcinomau

1988 • 34 citations

Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.

1986 • 33 citations

Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer

1996 • 33 citations

Aromatase Inhibitors

1995 • 28 citations

Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen

2000 • 28 citations

Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.

1997 • 24 citations

Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer

2005 • 23 citations

Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma

2001 • 23 citations

Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer

1994 • 23 citations

Phase III, Double-Blind, Controlled Trial of Atamestane Plus Toremifene Compared With Letrozole in Postmenopausal Women With Advanced Receptor-Positive Breast Cancer

2007 • 22 citations

A Randomised Comparison of Oestrogen Suppression with Anastrozole and Formestane in Postmenopausal Patients with Advanced Breast Cancer

1997 • 22 citations

Advanced breast cancer updates on anastrozole versus tamoxifen

2003 • 21 citations

Use of aromatase inhibitors in postmenopausal women with advanced breast cancer

1997 • 21 citations

A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex®) with intramuscular formestane in postmenopausal women with advanced breast cancer

1999 • 20 citations

Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment

1999 • 20 citations

ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer

1997 • 20 citations

Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma

1996 • 18 citations

Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer

1989 • 18 citations

Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer; A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age

2000 • 18 citations

Fadrozole hydrochloride, a new nontoxic aromatase inhibitor for the treatment of patients with metastatic breast cancer

1992 • 17 citations

Original article: CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer — A Phase I study

1990 • 16 citations

Sex hormone levels in postmenopausal women with advanced metastatic breast cancer treated with CGS 169 49A

1994 • 15 citations

Fadrozole versus Megestrol Acetate: A Double-Blind Randomised Trial in Advanced Breast Cancer

1998 • 15 citations

Open comparative trial of formestane versus megestrol acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen

2000 • 13 citations

Trial of aminoglutethimide vs hydrocortisone as second-line hormone treatment of advanced breast cancer.

1993 • 12 citations

Clinico-pharmacological aspects of different hormone treatments

2000 • 11 citations

Prospective Randomized Study of Aminoglutethimide (AG) versus Medroxyprogesterone Acetate (MPA) versus AG+MPA in Generalized Breast Cancer

1994 • 11 citations

Cost-effectiveness implications of increased survival with anastrozole in the treatment of advanced breast cancer

1999 • 11 citations

Second-Line Hormonotherapy for Breast Cancer

1993 • 9 citations

Effect of two 4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer

1994 • 9 citations

Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women

2002 • 6 citations

[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study for postmenopausal women with advanced or recurrent breast cancer (no. 1)--investigation of recommended clinical dose CGS20267 Study Group].

2002 • 4 citations

[Survival of breast cancer patients treated with inhibitors of the aromatase vs tamoxifen].

2004 • 4 citations

[Treatment of advanced metastatic breast cancer with exemestane, a multicenter randomized controlled study of 195 cases].

2003 • 2 citations

Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-ARM randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861)

1990 • 2 citations

[Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer].

1999 • 1 citations